|
|
|
|
Despite law, drug safety still a concern at FDA
WASHINGTON (Reuters) - Recent new powers have helped the U.S.Food and Drug Administration combat contaminated medications, counterfeit pills and other safety woes, but more work is needed to address lingering concerns about drug risks, FDA officials...
|
|
|
Despite law, drug safety still a concern at FDA
WASHINGTON (Reuters) Recent new powers have helped the U.S.Food and Drug Administration combat contaminated medications, counterfeit pills and other safety woes, but more work is needed to address lingering concerns about drug risks, FDA officials said...
|
|
|
Despite law, drug safety still a concern at FDA (Reuters)
WASHINGTON (Reuters) Recent new powers have helped the U.S.Food and Drug Administration combat contaminated medications, counterfeit pills and other safety woes, but more work is needed to address lingering concerns about drug risks, FDA officials said...
|
|
|
Despite law, drug safety still a concern at FDA
WASHINGTON (Reuters) - Recent new powers have helped the U.S.Food and Drug Administration combat contaminated medications, counterfeit pills and other safety woes, but more work is needed to address lingering concerns about drug risks, FDA officials...
|
|
|
FDA Advisory Committee Recommends Approval of InterMune's Esbriet(R) (pirfenidone) for ...
InterMune announced that the U.S.Food and Drug Administration's (FDA) Pulmonary-Allergy Drugs Advisory Committee (PADAC) voted 9-3 to recommend approval of Esbriet(R) (pirfenidone) for the treatment of patients with idiopathic pulmonary fibrosis (IPF)...
|
|
|
FDA: more changes coming on drug safety (Reuters)
WASHINGTON (Reuters) Recent new powers have helped the combat contaminated medications, counterfeit pills and other safety woes, but more work is needed to address lingering concerns about drug risks, FDA officials said on Wednesday.FDA...
|
|
|
FDA: more changes coming on drug safety
WASHINGTON (Reuters) - Recent new powers have helped the U.S.Food and Drug Administration combat contaminated medications, counterfeit pills and other safety woes, but more work is needed to address lingering concerns about drug risks, FDA officials...
|
|
|
FDA: more changes coming on drug safety
By Susan Heavey Susan Heavey 3 mins ago WASHINGTON (Reuters) Recent new powers have helped the U.S.Food and Drug Administration combat contaminated medications, counterfeit pills and other safety woes, but more work is needed to address lingering concerns...
|
|
|
CORRECTED: FDA: more changes coming on drug safety
By Susan Heavey Susan Heavey 15 mins ago WASHINGTON (Reuters) Recent new powers have helped the U.S.Food and Drug Administration combat contaminated medications, counterfeit pills and other safety woes, but more work is needed to address lingering concerns...
|
|
|
UPDATE 1-Despite law, drug safety still a concern at FDA
By Susan Heavey WASHINGTON, March 10 (Reuters) - Recent new powers have helped the U.S.Food and Drug Administration combat contaminated medications, counterfeit pills and other safety woes, but more work is needed to address lingering concerns about drug...
|
|
|
CORRECTED-UPDATE 1-US FDA: more changes coming on drug safety
By Susan Heavey WASHINGTON, March 10 (Reuters) - Recent new powers have helped the U.S.Food and Drug Administration combat contaminated medications, counterfeit pills and other safety woes, but more work is needed to address lingering concerns about drug...
|
|
|
CORRECTED-UPDATE 1-US FDA: more changes coming on drug safety
WASHINGTON, March 10 (Reuters) - Recent new powers have helped the U.S.Food and Drug Administration combat contaminated medications, counterfeit pills and other safety woes, but more work is needed to address lingering concerns about drug risks, FDA...
|
|
|
Despite law, drug safety still a concern at FDA
By Susan Heavey Susan Heavey 2 mins ago WASHINGTON (Reuters) Recent new powers have helped the U.S.Food and Drug Administration combat contaminated medications, counterfeit pills and other safety woes, but more work is needed to address lingering concerns...
|
|
|
Despite law, drug safety still a concern at FDA
By Susan Heavey Susan Heavey 37 mins ago WASHINGTON (Reuters) Recent new powers have helped the U.S.Food and Drug Administration combat contaminated medications, counterfeit pills and other safety woes, but more work is needed to address lingering concerns...
|
|
|
UPDATE 1-Despite law, drug safety still a concern at FDA
WASHINGTON, March 10 (Reuters) - Recent new powers have helped the U.S.Food and Drug Administration combat contaminated medications, counterfeit pills and other safety woes, but more work is needed to address lingering concerns about drug risks, FDA...
|
|
|
FDA: more changes coming on drug safety
FDA Commissioner Margaret Hamburg told lawmakers at a U.S.House of Representatives budget panel she was "moving forward with some strategies to enhance how we address drug safety." Hamburg declined to give details. But after the hearing, she told...
|
|
|
FDA's Advisory Committee votes 9-3 to recommend approval of Esbriet for treatment of patients with IPF
InterMune, Inc.(Nasdaq: ITMN) announced today that the U.S. Food and Drug Administration's (FDA) Pulmonary-Allergy Drugs Advisory Committee (PADAC) voted 9-3 to recommend approval of Esbriet (pirfenidone) for the treatment of patients with idiopathic...
|
|
|
PREVIEW-Will FDA approve Amylin, Lilly diabetes drug?
* FDA decision on once-weekly Byetta expected Friday LOS ANGELES, March 10 (Reuters) - Investors in Amylin Pharmaceuticals Inc (AMLN.O That's when the U.S.Food and Drug Administration is slated to decide whether to approve their long-acting diabetes...
|
|
|
FDA Advisory Committee Recommends Approval of InterMune's Esbriet (pirfenidone) for Idiopathic Pulmonary Fibro
-- InterMune to conduct conference call and webcast at 5:00 p.m.EST today -- BRISBANE, Calif., March 9 /PRNewswire-FirstCall/ -- InterMune, Inc. (NASDAQ:ITMN) announced today that the U.S. Food and Drug Administration's (FDA) Pulmonary-Allergy...
|
|
|
FDA Advisory Committee Recommends Approval of InterMune's Esbriet(R) (pirfenidone) for Idiopathic Pulmonary Fibrosis
BRISBANE, Calif., March 9 /PRNewswire-FirstCall/ -- InterMune, Inc.(Nasdaq: ITMN) announced today that the U.S. Food and Drug Administration's (FDA) Pulmonary-Allergy Drugs Advisory Committee (PADAC) voted 9-3 to recommend approval of Esbriet ...
|
|
|
FDA Advisory Committee Recommends Approval of InterMune, Inc. (ITMN)'s (JOBS) Esbriet(R) (pirfenidone) for Idi
BRISBANE, Calif., March 9 /PRNewswire-FirstCall/ -- InterMune, Inc.(Nasdaq:ITMN - News) announced today that the U.S. Food and Drug Administration's (FDA) Pulmonary-Allergy Drugs Advisory Committee (PADAC) voted 9-3 to recommend approval of Esbriet ...
|
|
|
FDA Advisory Committee Recommends Approval of InterMune's Esbriet(R) (pirfenidone) for Idiopathic Pulmonary Fi
-- InterMune to conduct conference call and webcast at 5:00 p.m.EST today -- BRISBANE, Calif., March 9 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) announced today that the U.S. Food and Drug Administrationescape_start39;s (FDA)...
|
|
|
InterMune's FDA Panel: Live Blog
Update 12:49 PM The FDA panel is on lunch break until 1 pm EST.The FDA review was tough, as I outlined below, but there is no clear indication yet about the direction of the experts on the panel. Only about half the panelists have spoken or...
|
|
|
NicOx announces FDA Advisory Committee to discuss naproxcinod on May 12
-NicOx S.A.(NYSE Euronext Paris: COX) today announces that on Wednesday, May 12, 2010, the US Food and Drug Administration (FDA) plans to hold a meeting of the Arthritis Drugs Advisory Committee and the Drug Safety and Risk Management Advisory...
|
|
|
FDA Advisory Committee Recommends Approval of InterMune's Esbriet(R) (pirfenidone) for Idiopathic Pulmonary Fibrosis
BRISBANE, Calif., March 9 /PRNewswire-FirstCall/ -- InterMune, Inc.(Nasdaq: ITMN) announced today that the U.S. Food and Drug Administration's (FDA) Pulmonary-Allergy Drugs Advisory Committee (PADAC) voted 9-3 to recommend approval of Esbriet ...
|
